169 related articles for article (PubMed ID: 11585424)
21. [-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-].
Kuhn W; Schmalfeldt B; Dose J; Pache L; Ulm K; Freitag K; Jänicke F; Graeff H
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):105-10. PubMed ID: 8647360
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer.
Fanning J; Colgrove M; Phibbs G
Gynecol Oncol; 2000 Oct; 79(1):97-100. PubMed ID: 11006039
[TBL] [Abstract][Full Text] [Related]
23. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
[TBL] [Abstract][Full Text] [Related]
24. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
Gynecol Oncol; 1999 Aug; 74(2):272-7. PubMed ID: 10419744
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.
Neijt JP; Engelholm SA; Witteveen PO; Tuxen MK; Sørensen PG; Hansen M; Hirsch F; Sessa C; de Swart C; van Houwelingen HC; Lund B; Hansen SW
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-36-S15-39. PubMed ID: 9346220
[TBL] [Abstract][Full Text] [Related]
26. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
[TBL] [Abstract][Full Text] [Related]
27. Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.
Bolis G; Scarfone G; Tateo S; Mangili G; Villa A; Parazzini F
Gynecol Oncol; 2001 Jan; 80(1):13-5. PubMed ID: 11136562
[TBL] [Abstract][Full Text] [Related]
28. Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer.
Morgan MA; Stadtmauer EA; Luger SM; Porter DL; Mangan PA; O'Neil P; Kamelle S; Benjamin I; Mick R; King SA; Rubin SC
Gynecol Oncol; 1997 Dec; 67(3):272-6. PubMed ID: 9441774
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy for malignant mixed Müllerian tumors of the ovary.
Sit AS; Price FV; Kelley JL; Comerci JT; Kunschner AJ; Kanbour-Shakir A; Edwards RP
Gynecol Oncol; 2000 Nov; 79(2):196-200. PubMed ID: 11063643
[TBL] [Abstract][Full Text] [Related]
30. [Chemotherapy for recurrent ovarian cancer].
Nishimura H; Imamura K; Chang C
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1124-8. PubMed ID: 8751798
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients.
Malmström H; Simonsen E; Westberg R
Gynecol Oncol; 1994 Jan; 52(1):20-5. PubMed ID: 8307496
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer.
Neijt JP; du Bois A
Semin Oncol; 1999 Feb; 26(1 Suppl 2):78-83. PubMed ID: 10190786
[TBL] [Abstract][Full Text] [Related]
33. Quality of life in ovarian cancer patients receiving chemotherapy.
Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel with carboplatin for the treatment of ovarian cancer.
Neijt JP; Lund B
Semin Oncol; 1996 Dec; 23(6 Suppl 15):2-4. PubMed ID: 8996588
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel and carboplatin for recurrent salivary gland malignancies.
Airoldi M; Fornari G; Pedani F; Marchionatti S; Gabriele P; Succo G; Bumma C
Anticancer Res; 2000; 20(5C):3781-3. PubMed ID: 11268454
[TBL] [Abstract][Full Text] [Related]
36. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.
Hensley ML; Hoppe B; Leon L; Sabbatini P; Aghajanian C; Chi D; Spriggs DR
Gynecol Oncol; 2001 Sep; 82(3):464-9. PubMed ID: 11520141
[TBL] [Abstract][Full Text] [Related]
37. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy.
Gershenson DM; Kavanagh JJ; Copeland LJ; Stringer CA; Morris M; Wharton JT
Obstet Gynecol; 1989 May; 73(5 Pt 1):798-802. PubMed ID: 2704508
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel does not cause central nervous adverse effects: a prospective vigilance-controlled EEG mapping study in ovarian cancer patients.
Mayerhofer K; Bodner K; Saletu B; Bodner-Adler B; Anderer P; Hefler L; Kaider A; Leodolter S; Kainz C
Wien Klin Wochenschr; 2000 Dec; 112(23):1007-13. PubMed ID: 11190709
[TBL] [Abstract][Full Text] [Related]
39. Salvage chemotherapy for epithelial ovarian carcinoma.
Christian MC; Trimble EL
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S143-50. PubMed ID: 7835799
[TBL] [Abstract][Full Text] [Related]
40. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Cancer; 2002 Apr; 94(7):1961-7. PubMed ID: 11932898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
